RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $34 to $35.
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $34 to $35.